Walvax Biotech Gains Majority Control of Fengmao Biotech
07:30 EDT 11 Jul 2012 | ChinaBio Today
Yunnan Walvax Biotechnology, a vaccine company, obtained a 51% stake in Shanghai Fengmao Biotechnology Co. Walvax will establish subsidiaries of Fengmao to produce five monoclonal antibodies and a sustained-release version of the anemia treatment..
Original Article: Walvax Biotech Gains Majority Control of Fengmao Biotech
More From BioPortfolio on "Walvax Biotech Gains Majority Control of Fengmao Biotech"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
